This CME activity is supported by an educational grant from Pfizer, New York, New
York.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Risk of cardiovascular events associated with selective COX-2 inhibitors.JAMA. 2001; 286: 954-959
- Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.JAMA. 2006; 296: 1633-1644
- Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.Circulation. 2004; 109: 2068-2073
- The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.Ann Intern Med. 2005; 142: 481-489
- Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.Lancet. 2005; 365: 475-481
- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.N Engl J Med. 2000; 343: 1520-1528
- Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.N Engl J Med. 2005; 352: 1092-1102
- Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.N Engl J Med. 2005; 352: 1081-1091
- Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.N Engl J Med. 2005; 352: 1071-1080
- Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.Circulation. 2006; 114: 1028-1035
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?.BMJ. 2006; 332: 1302-1308
- Cleveland Clinic launches large-scale global trial to examine cardiovascular safety of popular pain relievers.(Accessed July 25, 2008)
- The Editor's Roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk.Am J Cardiol. 2005; 96: 1589-1604
- The Steering Committee of the Physicians' Health Study Research Group.N Engl J Med. 1989; 321: 129-135
- Use of nonsteroidal anti-inflammatory drugs.Circulation. 2007; 115: 1634-1642
- 2006 safety alerts for drugs, biologics, medical devices, and dietary supplements: ibuprofen and aspirin taken together.(Accessed July 25, 2008)
- Pfizer for professionals.(Accessed July 25, 2008)
- Practical management of osteoarthritis: integration of pharmacologic and nonpharmacologic measures.Arch Fam Med. 1995; 4: 1049-1055
- Lifetime nonnarcotic analgesic use and decline in renal function in women.Arch Intern Med. 2004; 164: 1519-1524
- COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.Proc Natl Acad Sci U S A. 2002; 99: 13926-13931
- Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.JAMA. 2000; 284: 1247-1255
Article info
Footnotes
This discussion took place on April 22, 2008, at Baylor University Medical Center, Dallas, Texas.
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
